GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Income Statement History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| INCOME : | |||||
| Gross Sales | ₹27,709 Cr | ₹28,219 Cr | ₹27,805 Cr | ₹25,241 Cr | ₹10,641 Cr |
| Sales | ₹27,403 Cr | ₹27,990 Cr | ₹27,665 Cr | ₹25,094 Cr | ₹10,389 Cr |
| Job Work/ Contract Receipts | - | - | - | - | - |
| Processing Charges / Service Income | ₹129 Cr | ₹78 Cr | ₹8.49 Cr | ₹8.93 Cr | ₹7.90 Cr |
| Revenue from property development | - | - | - | - | - |
| Other Operational Income | ₹178 Cr | ₹151 Cr | ₹131 Cr | ₹138 Cr | ₹244 Cr |
| Less: Excise Duty | - | - | - | - | - |
| Net Sales | ₹11,813 Cr | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr |
| EXPENDITURE : | |||||
| Increase/Decrease in Stock | ₹-196 Cr | ₹-241 Cr | ₹-11 Cr | ₹-189 Cr | ₹128 Cr |
| Raw Material Consumed | ₹4,548 Cr | ₹4,445 Cr | ₹4,323 Cr | ₹3,809 Cr | ₹3,496 Cr |
| Opening Raw Materials | ₹649 Cr | ₹703 Cr | ₹528 Cr | ₹635 Cr | ₹637 Cr |
| Purchases Raw Materials | ₹3,027 Cr | ₹3,078 Cr | ₹3,380 Cr | ₹2,952 Cr | ₹2,465 Cr |
| Closing Raw Materials | ₹580 Cr | ₹649 Cr | ₹703 Cr | ₹528 Cr | ₹635 Cr |
| Other Direct Purchases / Brought in cost | ₹1,451 Cr | ₹1,312 Cr | ₹1,118 Cr | ₹750 Cr | ₹1,029 Cr |
| Other raw material cost | - | - | - | - | - |
| Power & Fuel Cost | ₹124 Cr | ₹112 Cr | ₹201 Cr | ₹165 Cr | ₹174 Cr |
| Electricity & Power | ₹124 Cr | ₹112 Cr | ₹201 Cr | ₹165 Cr | ₹174 Cr |
| Oil, Fuel & Natural gas | - | - | - | - | - |
| Coals etc | - | - | - | - | - |
| Other power & fuel | - | - | - | - | - |
| Employee Cost | ₹2,868 Cr | ₹2,601 Cr | ₹2,447 Cr | ₹2,344 Cr | ₹2,255 Cr |
| Salaries, Wages & Bonus | ₹2,641 Cr | ₹2,393 Cr | ₹2,238 Cr | ₹2,160 Cr | ₹2,063 Cr |
| Contributions to EPF & Pension Funds | ₹204 Cr | ₹187 Cr | ₹184 Cr | ₹165 Cr | ₹170 Cr |
| Workmen and Staff Welfare Expenses | ₹24 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹18 Cr |
| Other Employees Cost | - | ₹3.59 Cr | ₹7.92 Cr | ₹1.85 Cr | ₹3.08 Cr |
| Other Manufacturing Expenses | ₹1,013 Cr | ₹634 Cr | ₹785 Cr | ₹639 Cr | ₹669 Cr |
| Sub-contracted / Out sourced services | - | - | - | - | - |
| Processing Charges | ₹121 Cr | ₹98 Cr | ₹156 Cr | ₹114 Cr | ₹108 Cr |
| Repairs and Maintenance | ₹166 Cr | ₹153 Cr | ₹163 Cr | ₹148 Cr | ₹150 Cr |
| Packing Material Consumed | - | - | - | - | - |
| Other Mfg Exp | ₹727 Cr | ₹382 Cr | ₹466 Cr | ₹376 Cr | ₹411 Cr |
| General and Administration Expenses | ₹1,314 Cr | ₹1,212 Cr | ₹1,265 Cr | ₹1,028 Cr | ₹1,168 Cr |
| Rent , Rates & Taxes | ₹69 Cr | ₹66 Cr | ₹63 Cr | ₹77 Cr | ₹58 Cr |
| Insurance | ₹36 Cr | ₹37 Cr | ₹34 Cr | ₹30 Cr | ₹28 Cr |
| Printing and stationery | - | - | - | - | - |
| Professional and legal fees | ₹210 Cr | ₹244 Cr | ₹353 Cr | ₹269 Cr | ₹318 Cr |
| Traveling and conveyance | ₹283 Cr | ₹254 Cr | ₹182 Cr | ₹116 Cr | ₹238 Cr |
| Other Administration | ₹715 Cr | ₹612 Cr | ₹633 Cr | ₹536 Cr | ₹527 Cr |
| Selling and Distribution Expenses | ₹893 Cr | ₹1,137 Cr | ₹896 Cr | ₹943 Cr | ₹1,006 Cr |
| Advertisement & Sales Promotion | ₹516 Cr | ₹693 Cr | ₹543 Cr | ₹551 Cr | ₹704 Cr |
| Sales Commissions & Incentives | - | - | - | - | - |
| Freight and Forwarding | ₹377 Cr | ₹444 Cr | ₹353 Cr | ₹393 Cr | ₹302 Cr |
| Handling and Clearing Charges | - | - | - | - | - |
| Other Selling Expenses | - | - | - | - | - |
| Miscellaneous Expenses | ₹54 Cr | ₹48 Cr | ₹79 Cr | ₹121 Cr | ₹47 Cr |
| Bad debts /advances written off | ₹18 Cr | ₹13 Cr | - | - | - |
| Provision for doubtful debts | - | - | ₹30 Cr | ₹11 Cr | ₹18 Cr |
| Losson disposal of fixed assets(net) | - | - | ₹6.46 Cr | - | ₹1.17 Cr |
| Losson foreign exchange fluctuations | - | - | - | ₹75 Cr | - |
| Losson sale of non-trade current investments | - | - | - | - | - |
| Other Miscellaneous Expenses | ₹37 Cr | ₹35 Cr | ₹42 Cr | ₹35 Cr | ₹28 Cr |
| Less: Expenses Capitalised | - | - | - | - | - |
| Total Expenditure | ₹10,618 Cr | ₹9,948 Cr | ₹9,985 Cr | ₹8,860 Cr | ₹8,943 Cr |
| Operating Profit (Excl OI) | ₹1,195 Cr | ₹1,635 Cr | ₹2,320 Cr | ₹2,084 Cr | ₹1,698 Cr |
| Other Income | ₹840 Cr | ₹289 Cr | ₹167 Cr | ₹50 Cr | ₹160 Cr |
| Interest Received | ₹6.18 Cr | ₹7.00 Cr | ₹9.44 Cr | ₹2.65 Cr | ₹4.68 Cr |
| Dividend Received | ₹0.00 Cr | ₹0.35 Cr | ₹0.35 Cr | ₹0.35 Cr | ₹0.70 Cr |
| Profit on sale of Fixed Assets | ₹1.53 Cr | ₹5.73 Cr | - | ₹0.35 Cr | - |
| Profits on sale of Investments | - | - | - | - | - |
| Provision Written Back | - | - | - | - | - |
| Foreign Exchange Gains | - | ₹203 Cr | ₹88 Cr | - | ₹138 Cr |
| Others | ₹832 Cr | ₹72 Cr | ₹69 Cr | ₹47 Cr | ₹16 Cr |
| Operating Profit | ₹2,035 Cr | ₹1,924 Cr | ₹2,487 Cr | ₹2,135 Cr | ₹1,858 Cr |
| Interest | ₹516 Cr | ₹349 Cr | ₹298 Cr | ₹353 Cr | ₹377 Cr |
| InterestonDebenture / Bonds | - | ₹2.38 Cr | ₹32 Cr | ₹93 Cr | ₹84 Cr |
| Interest on Term Loan | ₹461 Cr | ₹288 Cr | ₹196 Cr | ₹223 Cr | ₹251 Cr |
| Intereston Fixed deposits | - | - | - | - | - |
| Bank Charges etc | - | - | - | - | - |
| Other Interest | ₹55 Cr | ₹59 Cr | ₹70 Cr | ₹38 Cr | ₹42 Cr |
| PBDT | ₹1,519 Cr | ₹1,575 Cr | ₹2,189 Cr | ₹1,781 Cr | ₹1,480 Cr |
| Depreciation | ₹582 Cr | ₹569 Cr | ₹487 Cr | ₹444 Cr | ₹417 Cr |
| Profit Before Taxation & Exceptional Items | ₹937 Cr | ₹1,006 Cr | ₹1,702 Cr | ₹1,338 Cr | ₹1,063 Cr |
| Exceptional Income / Expenses | ₹-901 Cr | ₹-766 Cr | ₹-261 Cr | ₹45 Cr | ₹33 Cr |
| Profit Before Tax | ₹36 Cr | ₹240 Cr | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr |
| Provision for Tax | ₹1,867 Cr | ₹329 Cr | ₹448 Cr | ₹412 Cr | ₹320 Cr |
| Current Income Tax | ₹1,116 Cr | ₹416 Cr | ₹547 Cr | ₹498 Cr | ₹396 Cr |
| Deferred Tax | ₹314 Cr | ₹-349 Cr | ₹-87 Cr | ₹-60 Cr | ₹-73 Cr |
| Other taxes | ₹438 Cr | ₹263 Cr | ₹-12 Cr | ₹-26 Cr | ₹-2.84 Cr |
| Profit After Tax | ₹-1,831 Cr | ₹-90 Cr | ₹994 Cr | ₹970 Cr | ₹776 Cr |
| Extra items | ₹397 Cr | ₹467 Cr | - | - | - |
| Minority Interest | ₹-68 Cr | ₹-80 Cr | ₹-52 Cr | ₹-0.05 Cr | ₹0.00 Cr |
| Share of Associate | - | - | - | - | - |
| Other Consolidated Items | - | - | - | - | - |
| Consolidated Net Profit | ₹-1,502 Cr | ₹297 Cr | ₹942 Cr | ₹970 Cr | ₹776 Cr |
| Adjustments to PAT | - | - | - | - | - |
| Profit Balance B/F | ₹9,457 Cr | ₹9,211 Cr | ₹7,234 Cr | ₹6,330 Cr | ₹5,615 Cr |
| Appropriations | ₹7,955 Cr | ₹9,508 Cr | ₹8,175 Cr | ₹7,300 Cr | ₹6,391 Cr |
| General Reserves | - | - | - | - | - |
| Proposed Equity Dividend | - | - | - | - | - |
| Corporate dividend tax | - | - | - | - | - |
| Other Appropriation | ₹85 Cr | ₹51 Cr | ₹-1,036 Cr | ₹66 Cr | ₹61 Cr |
| Equity Dividend % | ₹250.00 | ₹250.00 | ₹250.00 | ₹250.00 | ₹250.00 |
| Earnings Per Share | ₹-53.21 | ₹10.53 | ₹33.37 | ₹34.38 | ₹27.50 |
| Adjusted EPS | ₹-53.21 | ₹10.53 | ₹33.37 | ₹34.38 | ₹27.50 |
Compare Income Statement of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹55,477.7 Cr | 1.2% | 3.6% | 29.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹433,248.0 Cr | -0.2% | 5.8% | 0.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,344.0 Cr | -0.6% | -5.2% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹125,832.0 Cr | -0.5% | 2.5% | 12.1% | Stock Analytics | |
| CIPLA | ₹121,820.0 Cr | -1.1% | -0.2% | -1.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,877.0 Cr | 2.4% | 7% | 6.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.2% |
3.6% |
29.6% |
| SENSEX | -0.6% |
1.4% |
7.7% |
You may also like the below Video Courses